Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Nuclear transcription factor (NF-κB) >  IκB / IKK inhibitors >  IKK Inhibitor III, BMS-345541

IKK Inhibitor III, BMS-345541

Basic information Safety Supplier Related

IKK Inhibitor III, BMS-345541 Basic information

Product Name:
IKK Inhibitor III, BMS-345541
Synonyms:
  • IKK Inhibitor III, BMS-345541
  • BMS 345541 (free base)
  • BMS345541 (free base)
  • BMS-345541 (free base)
  • N-(1,8-Dimethylimidazo[1,2-a]quinoxalin-4-yl)-1,2-ethanediamine
  • 1,2-Ethanediamine, N1-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)-
  • N-(1,8-Dimethylimidazo[1,2-a]quinoxalin-4-yl)-1,2-ethanediamine BMS345541
  • N1-(1,8-Dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine
CAS:
445430-58-0
MF:
C14H17N5
MW:
255.32
Product Categories:
  • IκB/IKK
  • Inhibitors
  • A cell-permeable quinoxaline compound that displays anti-inflammatory properties.
  • IKK
Mol File:
445430-58-0.mol
More
Less

IKK Inhibitor III, BMS-345541 Chemical Properties

Boiling point:
449.5±45.0 °C(Predicted)
Density 
1.32±0.1 g/cm3(Predicted)
storage temp. 
under inert gas (nitrogen or Argon) at 2–8 °C
solubility 
insoluble in H2O; ≥70 mg/mL in DMSO; ≥2.49 mg/mL in EtOH with gentle warming and ultrasonic
form 
Powder
pka
9.02±0.10(Predicted)
CAS DataBase Reference
445430-58-0
More
Less

IKK Inhibitor III, BMS-345541 Usage And Synthesis

Characteristics

Allosteric IKK inhibitors have anti-inflammatory activity.

Uses

BMS-345541 is a potent, selective, and allosteric site-binding inhibitor of IKK β (IKK-2) and shows 10 times greater selectivity over IKK α (IKK-1). BMS-345541 also inhibits cellular Iκβα phosphorylation and has some anti-inflammatory properties.

Definition

ChEBI: N'-(1,8-dimethyl-4-imidazo[1,2-a]quinoxalinyl)ethane-1,2-diamine is a quinoxaline derivative.

Biological Activity

BMS-345541 highly selectively inhibits the catalytic subunits of IKK-2 and IKK-1 with IC50s of 0.3 μM and 4 μM, respectively.

in vitro

BMS-34554 (5 μM) induces time-dependent dephosphorylation of IκBα and p65. Treatment of T-ALL cells with BMS-34554 resulted in nuclear translocation of FOXO3a, including control of the expression level of the p21CIP1 gene. In human umbilical vein endothelial cells, BMS-345541 inhibits TNFα-induced expression of ICAM-1 and VCAM-1 with IC50 of 5 μM.

in vivo

BMS-345541 (100 mg/kg) reduced the cumulative arthritis damage score from 4.4 to 0, along with low-grade degradation and inflammation of the tibiotarsal joint, synovial hyperplasia, bone resorption, and severity of cartilage erosion. There was no apparent damage to the joints of the animals, which was indistinguishable from the histological phenotype observed in those from age-matched, disease-free control animals. BMS-345541 dose-dependently inhibited IL-1β signaling, with animals in the 100 mg/kg dose group exhibiting levels consistent with disease-free control animals.

target

TargetValue
IKK2
(Cell-free assay)
0.3 μM
IKK1
(Cell-free assay)
4 μM

IKK Inhibitor III, BMS-345541Supplier

VDM Biochemicals
Tel
0330-2528181
Email
sales@vdmbio.com
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Tianjin Derchemist Science & Technology Co., Ltd.
Tel
22-58627059 13920586291
Email
zdcomcon@126.com
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399 18927568969
Email
isunpharm@qq.com
More
Less